DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 126 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 1.42 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $377,860 | -73.1% | 29,706 | -70.2% | 0.00% | -75.0% |
| Q2 2023 | $1,403,860 | -49.2% | 99,706 | -44.2% | 0.00% | -50.0% |
| Q1 2023 | $2,761,008 | -53.0% | 178,706 | -50.2% | 0.01% | -55.6% |
| Q4 2022 | $5,876,684 | +2.9% | 358,553 | +16.1% | 0.02% | -5.3% |
| Q3 2022 | $5,711,000 | +176.6% | 308,700 | +96.5% | 0.02% | +171.4% |
| Q2 2022 | $2,065,000 | +38.5% | 157,069 | +2.9% | 0.01% | +133.3% |
| Q4 2021 | $1,491,000 | -74.5% | 152,649 | +56.0% | 0.00% | -89.7% |
| Q2 2020 | $5,844,000 | +19.6% | 97,854 | -17.5% | 0.03% | -27.5% |
| Q1 2020 | $4,885,000 | +57.3% | 118,655 | +137.8% | 0.04% | +344.4% |
| Q4 2019 | $3,105,000 | +123.1% | 49,895 | +21.6% | 0.01% | +80.0% |
| Q3 2019 | $1,392,000 | +197.4% | 41,021 | +244.7% | 0.01% | +400.0% |
| Q2 2018 | $468,000 | – | 11,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $18,687,872 | 15.44% |
| Redmile Group, LLC | 5,582,105 | $86,243,522 | 3.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,218,638 | $80,627,957 | 1.80% |
| BRAIDWELL LP | 3,241,351 | $50,078,873 | 1.65% |
| Parkman Healthcare Partners LLC | 491,772 | $7,597,877 | 1.65% |
| Sunesis Advisors, LLC | 96,299 | $1,487,820 | 1.07% |
| ARMISTICE CAPITAL, LLC | 4,100,000 | $63,345,000 | 0.91% |
| Deep Track Capital, LP | 1,363,201 | $21,061,455 | 0.86% |
| AlphaCentric Advisors LLC | 72,500 | $1,120,125 | 0.77% |
| Ikarian Capital, LLC | 174,510 | $2,696,179 | 0.61% |